secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001178913-23-000679
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab receives FDA clearance to start Phase 2 trial of CM-101 in systemic sclerosis
--------------------------------------------------------------------------------

- FDA cleared IND for Phase 2 ABATE trial of CM-101 in systemic sclerosis (SSc).
- CM-101 is a first-in-class monoclonal antibody targeting CCL24; has Orphan Drug designation for SSc and PSC.
- Trial to enroll 45 patients; primary endpoint safety; top-line data expected H2 2024.
- CM-101 previously well-tolerated in early trials, reduced fibro-inflammatory biomarkers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323000679/0001178913-23-000679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323000679/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-23-000679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer